Prognostic implications of myelodysplasia-related gene mutations in NPM1 -mutated acute myeloid leukemia: a systematic review and meta-analysis.
Yu-Sung Chang, Yi-Wei Lee, Chieh-Yu Liu et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed whether myelodysplasia-related gene (MRG) mutations affect prognosis in NPM1-mutated acute myeloid leukemia. Ten cohorts from nine studies included 4,363 patients; 655 (15.0%) had co-occurring MRG mutations. MRG mutations were associated with inferior overall survival (pooled HR=1.30; 95% CI: 1.11-1.51; P<0.001), shorter event-free survival, and lower complete remission rates. Adverse associations were also reported among patients receiving intensive therapy and those classified as ELN-2022 favorable risk.
Key findings
- MRG mutations were present in 655 of 4,363 patients (15.0%).
- MRG mutations were associated with inferior overall survival (pooled HR=1.30; 95% CI: 1.11-1.51; P<0.001; I²=39.2%).
- Event-free survival was shorter with MRG mutations (HR=1.43; 95% CI: 1.11-1.85; P=0.006; I²=18.2%).
- Complete remission rates were lower with MRG mutations (risk ratio=0.94; 95% CI: 0.90-0.99; P=0.01; I²=0.0%).
Why it matters
NPM1-mutated AML is generally considered favorable risk under ELN-2022 criteria, but these pooled findings indicate that co-occurring MRG mutations may identify patients with poorer outcomes, including within the favorable-risk group. Recognising this potential heterogeneity may help inform future refinement of prognostic classification, while the evidence remains based on pooled cohort studies.
What to keep in mind
The analysis pooled observational cohorts, so the associations do not establish that MRG mutations cause poorer outcomes. Results also showed some heterogeneity for overall survival (I²=39.2%).